AI Updates Aggregator

🌍The Next Web (TNW)•Jun 17, 2026Stalecollected in 42m

Paradromics implants first brain-computer interface in patient

Post LinkedIn

🌍Read original on The Next Web (TNW)

#neurotech #bci #biotechconnexus

💡A new major competitor enters the BCI space, challenging Neuralink's dominance.

⚡ 30-Second TL;DR

What Changed

Paradromics implants Connexus BCI in first human patient

Why It Matters

The entry of a second major player into the BCI market accelerates the pace of innovation in neural signal processing. It increases the likelihood of rapid regulatory and clinical advancements for assistive technologies.

What To Do Next

Research the signal processing algorithms used in BCI platforms to understand the data requirements for neural decoding.

Who should care:Researchers & Academics

🧠 Deep Insight

Web-grounded analysis with 21 cited sources.

🔑 Enhanced Key Takeaways

•Paradromics, founded in 2015, has secured approximately $88.7 million in total funding across 13 rounds, including an initial $18 million from the United States Defense Advanced Research Projects Agency (DARPA).
•The Connexus BCI received two FDA Breakthrough Device Designations in May 2023, recognizing its potential for both speech restoration and control of computer devices, which facilitates an expedited regulatory review process.
•Preclinical testing of the Connexus BCI has demonstrated an information transfer rate exceeding 200 bits per second (bps) with a latency of 56 milliseconds, and over 100 bps with a latency of 11 milliseconds for latency-sensitive applications.
•The Connect-One clinical study, which received FDA Investigational Device Exemption (IDE) approval in November 2025, is designed to evaluate the long-term safety and efficacy of the Connexus BCI in restoring speech and enabling computer control for individuals with severe motor impairment.
•The Connexus BCI utilizes 421 ultra-thin electrodes, made of platinum-iridium and thinner than a human hair, which are designed to extend 1.5 mm into the brain's auditory cortex to record individual neural signals.

📊 Competitor Analysis▸ Show

Company	Device	Invasiveness	Electrode Count	Data Rate/Latency	Key Focus/Features
Paradromics	Connexus BCI	Intracortical	421	>200 bps @ 56ms, >100 bps @ 11ms	Speech restoration, computer control, fully implantable, wireless, high-fidelity data acquisition
Neuralink	N1	Intracortical	1,024 (on 64 threads)	High resolution, 7-10 bps control speeds reported	Cursor control, speech, vision restoration, robotic implantation, fully wireless
Synchron	Stentrode	Endovascular (less invasive)	16	Lower resolution	Basic digital interaction, lower surgical risk, implanted via jugular vein
Blackrock Neurotech	Utah Array	Intracortical	100-128	High-quality scientific data	Motor control, longest clinical track record, percutaneous connectors (wired)
Precision Neuroscience	Layer 7 Cortical Interface	Surface ECoG (partially invasive)	1,024	Hundreds of contacts	Safety testing, data gathering, thin-film microelectrode array, minimally invasive cranial micro-slit

🛠️ Technical Deep Dive

The Connexus BCI consists of an implantable high-density microelectrode array that records neural signals and a discrete transceiver in the chest that wirelessly transmits data through the skin to an external receiver.
It features 421 ultra-thin electrodes, each approximately 40 microns in diameter and made of platinum-iridium, designed to extend 1.5 mm into the brain tissue, specifically the auditory cortex for speech-related applications.
The system is engineered for chronic stability and long-term daily use, aiming to withstand harsh biological conditions.
Advanced artificial intelligence algorithms are used to decode the recorded brain activity, translating neural signals into text, synthesized speech, or computer commands.
Paradromics has developed SONIC, an open benchmarking standard to rigorously measure BCI performance, demonstrating information transfer rates over 200 bits per second with 56ms latency and over 100 bits per second with 11ms latency in preclinical models.

🔮 Future ImplicationsAI analysis grounded in cited sources

Paradromics will significantly advance speech restoration capabilities for individuals with severe motor impairment.

The Connexus BCI's high data-rate platform and the specific focus of its Connect-One clinical study on restoring speech position the company to make substantial progress in this critical area.

The invasive BCI market will increasingly specialize in high-bandwidth applications for complex neurological functions.

Paradromics' emphasis on high data rates for speech, alongside competitors like Neuralink pursuing similar high-performance goals, indicates a trend towards devices optimized for specific, high-resolution brain-computer interaction tasks.

⏳ Timeline

2015

Paradromics founded by Matt Angle.

2016

Received NIH SBIR grant and a DARPA contract for approximately $18 million.

2018-05

Raised $7 million in seed funding.

2023-05

Connexus BCI granted first FDA Breakthrough Device Designation.

2025-06

Completed first successful temporary Connexus BCI implantation in a human during epilepsy research.

2025-11

Received FDA Investigational Device Exemption (IDE) approval for the Connect-One clinical study.

📎 Sources (21)

Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.

🌍Read original article on The Next Web (TNW)

📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #neurotech

Same product

AI-curated news aggregator. All content rights belong to original publishers.
Original source: The Next Web (TNW) ↗

⚡ 30-Second TL;DR

🧠 Deep Insight

🔑 Enhanced Key Takeaways

🛠️ Technical Deep Dive

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline

📎 Sources (21)

👉Related Updates

Meta's brain-reading AI advances beyond character-level decoding

Astellas cuts price of gastric cancer drug by 30%

Taiwan debates NT$240bn investment in drone defense systems

Chrome's silent background updates raise privacy concerns